Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 9/20 | 0.51 |
| ▸ | PAICS | P22234 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PHKG1 | Q16816 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319767 | 0.92 | TGFBR1 (0.60) | TGFBR1MAP4K4METFLT3ROCK2 | |
| SCHEMBL320854 | 0.90 | TGFBR1 (0.59) | TGFBR1MAP4K4FLT3ROCK2PHKG1 | |
| SCHEMBL320469 | 0.85 | TGFBR1 (0.44) | TGFBR1MAP4K4MET | |
| SCHEMBL2325058 | 0.84 | TGFBR1 (0.41) | TGFBR1MAP4K4PAICSMETFLT3 | |
| SCHEMBL10153774 | 0.82 | PAICS (0.44) | TGFBR1MAP4K4PAICSMETFLT3 | |
| SCHEMBL12440047 | 0.78 | TGFBR1 (0.46) | TGFBR1MAP4K4METKDR | |
| SCHEMBL320460 | 0.77 | TGFBR1 (0.48) | TGFBR1MAP4K4METKDR | |
| SCHEMBL320451 | 0.77 | TGFBR1 (0.53) | TGFBR1MAP4K4MET | |
| SCHEMBL320657 | 0.74 | TGFBR1 (0.51) | TGFBR1MAP4K4MET | |
| SCHEMBL320493 | 0.74 | TGFBR1 (0.46) | TGFBR1MAP4K4PAICSKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| EP-2590946-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | Merck Patent GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | TGFBR1 1/4885MAP4K4 98/4885PAICS 1301/4885 |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | TGFBR1 1/4885MAP4K4 98/4885PAICS 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.